Bristol-Myers Squibb - A global biopharmaceutical company
Multiple Myleoma
Harnessing the Potential of Natural Killer Cells, Exploring Novel Pathways Against Multiple Myeloma Multiple myeloma, or simply myeloma, is the second most common blood cancer and remains largely incurable with less than half of myeloma patients surviving five years after diagnosis. Natural killer (NK) cells are among the body’s first line of defense in recognizing and eliminating cancerous cells and may play an important role in the immune response to myeloma.
Learn more

Clinical Trials and Research Learn about Bristol-Myers Squibb's
Clinical Trial Activities and
Investigator-Sponsored Research
Health Care Professionals Access medical information and resources
Need Help Paying for Your
Bristol-Myers Squibb Medicines?
Learn about our assistance programs.
Patients and
Learn about clinical trial participation at
Bristol-Myers Squibb
Study Connect


You are leaving to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.